Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28645934)

Published in J Am Heart Assoc on June 23, 2017

Authors

Ziad Hijazi1,2, Bertil Lindahl3,2, Jonas Oldgren3,2, Ulrika Andersson3, Johan Lindbäck3, Christopher B Granger4, John H Alexander4, Bernard J Gersh5, Michael Hanna6, Veli-Pekka Harjola7, Elaine M Hylek8, Renato D Lopes4, Agneta Siegbahn3,9, Lars Wallentin3,2

Author Affiliations

1: Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden ziad.hijazi@ucr.uu.se.
2: Department of Medical Sciences, Cardiology, Uppsala University, Uppsala Sweden.
3: Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
4: Duke University Medical Center, Durham, NC.
5: Mayo Clinic College of Medicine, Rochester, MN.
6: Bristol-Myers Squibb, Princeton, NJ.
7: Division of Emergency Care, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland.
8: Boston University Medical Center, Boston, MA.
9: Department of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden.

Associated clinical trials:

Anticoagulant and Antiarrhythmic Management Based on Continuous Rhythm Monitoring | NCT04038944

Articles by these authors

The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet (2016) 3.02

Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. Heart (2014) 1.53

Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol (2016) 1.43

Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart (2016) 1.41

Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Am Heart J (2014) 0.93

High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. J Am Coll Cardiol (2013) 0.92

Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. Am Heart J (2014) 0.92

Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J (2014) 0.86

Acute heart failure with and without concomitant acute coronary syndromes: patient characteristics, management, and survival. J Card Fail (2014) 0.82

Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. Clin Chem (2016) 0.80

Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry. J Am Heart Assoc (2016) 0.77

Family history of atrial fibrillation is associated with earlier-onset and more symptomatic atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J (2016) 0.77

History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J (2016) 0.77

The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. Eur Heart J (2016) 0.76

Response to letter regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis". Circulation (2014) 0.75

The ABC risk score for patients with atrial fibrillation - Authors' reply. Lancet (2016) 0.75

Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome. J Thromb Thrombolysis (2017) 0.75

Patient factors associated with quality of life in atrial fibrillation. Am Heart J (2016) 0.75

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. J Am Heart Assoc (2017) 0.75

Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. Am J Med (2017) 0.75

Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights From the ARISTOTLE Trial. Am J Med (2017) 0.75

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol (2016) 0.75

Relationship between therapeutic effects on infarct size in acute myocardial infarction and therapeutic effects on 1-year outcomes: A patient-level analysis of randomized clinical trials. Am Heart J (2017) 0.75

Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Am Heart J (2017) 0.75

Risk factors for exclusive breastfeeding lasting less than two months-Identifying women in need of targeted breastfeeding support. PLoS One (2017) 0.75

Idarucizumab since FDA approval: Use in the real-world. Am Heart J (2017) 0.75

Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. J Am Coll Cardiol (2017) 0.75

Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J Am Heart Assoc (2017) 0.75

A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J (2017) 0.75

Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J (2016) 0.75

Comparison of Bleeding Risk Scores in Patients with Atrial Fibrillation:Insights from the RE-LY Trial. J Intern Med (2017) 0.75

Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: Insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trials. Am Heart J (2015) 0.75